PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-20.40%
Negative net income growth while Biotechnology median is -1.76%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
5.37%
D&A growth of 5.37% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
42.67%
Deferred tax growth of 42.67% while Biotechnology median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
-15.52%
SBC declines yoy while Biotechnology median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
2.45%
Working capital of 2.45% while Biotechnology median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.66%
AP shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
389.89%
Growth of 389.89% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-15.52%
Other non-cash items dropping yoy while Biotechnology median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-26.74%
Negative CFO growth while Biotechnology median is -6.06%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
51.76%
CapEx growth of 51.76% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Investment purchases shrink yoy while Biotechnology median is 0.00%. Seth Klarman would see a short-term cash advantage if no high-return opportunities are missed.
No Data
No Data available this quarter, please select a different quarter.
169.66%
Growth of 169.66% while Biotechnology median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
253.33%
Investing flow of 253.33% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
100.00%
Debt repayment growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
-79.28%
We reduce issuance yoy while Biotechnology median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.